HJF Signs CRADA with Defense Health Agency

United States

The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) and the Defense Health Agency (DHA) on July 26 signed a master Cooperative Research and Development Agreement (CRADA) that also included two other foundations (Geneva and Metis). The CRADA was signed by Dr. La Shaun J. Berrien, HJF Vice President of Research Administration & Innovation Management, and Robert J. Bolluyt, Director, Technology Transfer & Intellectual Property, Deputy Assistant Director for Acquisition & Sustainment, Assistant Director – Support, Defense Health Agency.

A CRADA is a written agreement that facilitates research and development (R&D) collaboration between one or more federal laboratories and one or more non-federal entities. The newly signed DHA Master CRADA now gives HJF the authority to enter into grants, contracts, other transactions, material transfer agreement, non-disclosure, and clinical trial agreements directly with the research sponsors (federal and non-federal).

“This new process will speed up the CRADA process considerably,” said Stephen Dalal, HJF Vice President of U.S. Research Development. “It reduces the number of parties to each CRADA from three to two and allows HJF to directly negotiate with these sponsors and not have to wait for an individual CRADA office at a site to review each agreement.”

About HJF: 
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), now celebrating its 40 th anniversary, is a global nonprofit organization with the mission to advance military medicine. HJF’s scientific, administrative and program operations services empower investigators, clinicians, and medical researchers around the world to make discoveries in all areas of medicine. HJF serves as a trusted and responsive link between the military medical community, federal and private partners, and the millions of warfighters, veterans, and civilians who benefit from military medicine. For more information, visit